Physician profile
Stuart D Russell
NPI 1669407854
$25,743.94
in general payments reported to CMS, 2019-2025
23 companies · $2,520 in 2025
The $2,520 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,598 · 2020: $3,862 · 2021: $3,245 · 2022: $3,791 · 2023: $2,720 · 2024: $1,007 · 2025: $2,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,250 · Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,250.00 |
| Food and Beverage | $997.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,173.14 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Medtronic Vascular, INC. | $10,001.76 | 2019-2020 | |
| Medtronic, INC. | $2,275.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,943.77 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $437.30 | 2019-2025 | Lifevest |
| Abiomed | $156.18 | 2021-2024 | Impella |
| Janssen Pharmaceuticals, INC | $123.74 | 2019-2022 | |
| Edwards Lifesciences Corporation | $98.56 | 2025 | Evoque |
| Actelion Pharmaceuticals US, INC. | $96.94 | 2023 | Uptravi, Opsumit |
| Boston Scientific Corporation | $58.91 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $56.28 | 2019 | |
| Akcea Therapeutics, INC. | $52.64 | 2020 | |
| Pfizer INC. | $49.55 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.77 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $40.37 | 2023-2024 | Inpefa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $33.18 | 2019 | |
| Irhythm Technologies, INC. | $28.29 | 2024 | Zio Monitor, Zio Xt Patch |
| Scpharmaceuticals INC. | $24.34 | 2023 | |
| Novo Nordisk INC | $17.36 | 2023 | Ozempic |
| Daiichi Sankyo INC. | $16.84 | 2023 | Injectafer |
| Janssen Scientific Affairs, LLC | $15.02 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.